Last reviewed 2026-04-22 · How we verify

ITI

ITI is an immune tolerance induction therapy that uses a combination of immunosuppressive agents to induce tolerance to factor VIII in hemophilia A patients with inhibitors.

ITI is an immune tolerance induction therapy that uses a combination of immunosuppressive agents to induce tolerance to factor VIII in hemophilia A patients with inhibitors. Used for Hemophilia A with factor VIII inhibitors.

At a glance

Mechanism of action

ITI works by suppressing the immune system's response to factor VIII through a regimen typically involving factor VIII infusions combined with immunosuppressive drugs (such as cyclophosphamide and corticosteroids). The goal is to eliminate or reduce factor VIII inhibitor antibodies, allowing patients to safely use factor VIII replacement therapy again. This approach aims to restore immune tolerance rather than simply managing inhibitor levels.

Approved indications

• Hemophilia A with factor VIII inhibitors

Common side effects

• Infection
• Immunosuppression-related complications
• Thrombosis

Key clinical trials

• rTMS for Aneroxia Nervosa in Youth (NA)
• Prognostic Value of (DHODH) Expression in (HGSOC): A Comparative Study Between Neoadjuvant and Adjuvant Chemotherapy Settings
• Menstrual Cycle TMS Plasticity Pilot
• Resting State Changes Following Theta Burst Stimulation (NA)
• Influence of TMS on Attention Modulation (NA)
• A Combined Neurofeedback-TMS Intervention for Alcohol Use Disorder (NA)
• A Phase 2b Dose Finding Study of RMC-035 in Participants Undergoing Open-chest Cardiac Surgery (PHASE2)
• Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ITI 333 in Healthy Volunteers (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.